Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





New Rapid, Saliva-Based COVID-19 Antigen Test Could Be More Affordable, Sensitive, and Easy to Use

By LabMedica International staff writers
Posted on 08 Apr 2021
A portable, smartphone-powered device that comes with a simple saliva collection kit could make rapid testing for COVID-19 more accessible and easier to deploy

Nicoya Lifesciences (Ontario, Canada) is developing a saliva-based, portable and rapid COVID-19 diagnostic test, called Atlas, that is able to provide PCR levels of performance without the need for complex lab equipment or highly trained technicians, unlike other point-of-care diagnostics. More...
Atlas is a low-cost, single-use device that tests for active SARS-CoV-2 infection via viral antigen detection. Users will be able to self-administer the test with a simple saliva collection kit and smartphone application that will take them from sample to answer in under 20 minutes. These benefits increase the accessibility of the test which will result in Atlas becoming more widely adopted globally.

Its differentiated supply chain also ensures that it can be manufactured at scale. This is a vital resource alongside vaccine distribution to help slow and end the pandemic by identifying the virus in people before it can continue to spread. Atlas will meet the demand for widespread testing because it doesn’t require a lab, trained professionals, or 2-5 days to process results like commonly used RT-PCR tests. As a platform technology, Atlas is well suited to adapt to the rapidly changing nature of the SARS-CoV-2 virus, allowing it to remain effective towards viral variants and help mitigate future crises. As a test that is affordable, sensitive, and easy to use, Atlas will be widely accessible on the global stage. Nicoya is receiving additional advisory services and funding to continue research and development of its rapid, saliva-based COVID-19 antigen test.

"In a short period of time, our team was able to leverage years of experience to develop a completely novel method of viral detection that solves many of the issues with the current point-of-care tests," said Ryan Denomme, co-founder and CEO of Nicoya. "Combining ease-of-use and affordability while still maintaining the highest levels of performance makes Atlas a powerful tool to combat this and future pandemics.

"Looking beyond the COVID-19 pandemic, Atlas will allow communities around the world to be better prepared for future viral outbreaks," added Arjun Sudarsan, PhD, Chief Technical Officer at Nicoya. "As we saw over the last year, we were unprepared for a pandemic of this magnitude. By adopting a portable test like Atlas, countries can ensure they have the capabilities needed to scale up diagnostic testing, while also providing individual users with accessible and effective testing. This platform-based approach to diagnostic testing will help prepare the world for viral outbreaks beyond SARS-CoV-2."

Related Links:
Nicoya Lifesciences


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Portable Electronic Pipette
Mini 96
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
New
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: AiPlex VAS for the MosaiQ platform is designed to help reduce time-to-diagnosis for patients with autoimmune vasculitis (Photo courtesy of AliveDx)

Novel Multiplex Assay Supports Diagnosis of Autoimmune Vasculitis

Autoimmune vasculitis and related conditions are difficult to diagnose quickly and accurately, often requiring multiple tests to confirm the presence of specific autoantibodies. Traditional methods can... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.